International Society for Cell & Gene Therapy 2024
At the forefront of oncological innovation, Syneos Health spearheads the advancement of cell and gene therapies (CGT), heralding a transformative era in the battle against cancer. With decades of pioneering experience, the Syneos Health Cell and Gene Therapy Development Engine is making groundbreaking strides in therapy development and commercialization, committed to revolutionize patient care with leading-edge research and therapies tailored to individual needs.
Our dedication extends to clinical site innovation, where we make strategic investments and form key partnerships to propel these therapies forward. By fostering an ecosystem that encourages scientific exploration and application, we aim to not only advance the current state of CGT but to shape its future, bringing hope and healing to patients worldwide.
Meet with Us
Join us at ISCT 2024, where we aim to forge alliances that harness our collective insights and expertise. Together, we can tailor solutions that meet the unique demands of each trial, prioritizing safety, efficacy, and the expedited delivery of groundbreaking treatments to patients who need them most.
Our Attendees
Abhi Gupta, Senior Vice President & Head of Cell and Gene Therapy, Syneos Health
Abhi Gupta joined Syneos Health in April 2023 as Senior Vice President, Head of Cell and Gene Therapy. In his role, he drives the development and operationalization of strategic clinical and commercial solutions that accelerate the impact of life-changing genetic medicines for Syneos Health customers and their patients. Prior to Syneos Health, Abhi held various leadership and scientific positions at Pfizer, Regeneron, Citigroup, BMS, and Johnson & Johnson. He is passionate about improving the real-world life experiences of genetic medicine patients and their families and overcoming the pressing challenges of cell and gene therapy research.
Jane K. Bentley, PhD, Vice President, Therapeutic Strategy & Innovation, Oncology and Hematology, Syneos Health
Jane is a distinguished professional in the pharmaceutical industry with over 35 years of experience in oncology drug development. Since May 2016, Jane has been with Syneos Health, where she is passionate about driving strategic innovation in oncology. Her work involves collaborating closely with clients and internal teams to develop and implement solutions-based approaches to drug development, ensuring that new therapies are developed efficiently and effectively. Jane's leadership extends to spearheading cross-functional innovation initiatives, focusing on the patient voice, cell and gene therapy, and rare disease, underlining her dedication to incorporating patient perspectives and addressing the challenges of complex treatments.
Contenu apparenté
Vous voulez en savoir plus? Explore Insights Hub for our latest perspectives, subscribe to our podcast, or click the resources below:
A Holistic Approach to Genetic Medicines is Next for the Life Science Industry
Exploring an Expedited Regulatory Pathway for Cell and Gene Therapies
Cell and Gene Therapy Sponsors Must Overcome Unique Hurdles to Realize Promise to Patients
Strategies for Small Biotech in the Development of Cell Therapy Trials
View more of our insights on Cell & Gene Therapy.
Learn more about our Cell & Gene Therapy expertise.
